{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:34:13Z","timestamp":1781602453291,"version":"3.54.5"},"reference-count":40,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2010,4,2]],"date-time":"2010-04-02T00:00:00Z","timestamp":1270166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>This study researches the efficacy and safety of pegylated interferon alpha-2a (pegIFN\u03b1-2a) in Egyptian children and adolescents diagnosed with hepatitis C virus. Thirty patients were enrolled to receive pegIFN once a week with ribavirin twice daily for 12 weeks; viral load and experienced adverse effects were then assessed. Of the 30 patients, 16 (53.33%) were cleared from the virus, showing early virologic response (EVR). Three patients (10%) showed a 2-log reduction by week 12, with an overall early response rate of 63.33%. Three patients who showed EVR after 4 weeks relapsed by week 12. Levels of serum alanine aminotransferase (ALT) normalized at week 12. Adverse events included fever, myalgia, headache, flu-like symptoms, fatigue, anemia, and leucopenia; 63.33% of the patients showed significant reduction in their body weight. Although the patients showed a reduction in average body mass index, this reduction was not significant. Hemoglobin values decreased within the first 2 weeks and then stabilized but not back to baseline. A significant reduction in the level of absolute neutrophil count (ANC) was observed by the 4th week and started to improve by the 12th week. Of the recruited patients, 29.4% were subjected to IFN dose reduction. None of the patients with neutropenia developed serious infection or sepsis. The authors concluded that pegIFN plus ribavirin therapy is promising when tested on Egyptian children.<\/jats:p>","DOI":"10.1177\/0897190010367737","type":"journal-article","created":{"date-parts":[[2010,4,5]],"date-time":"2010-04-05T13:44:31Z","timestamp":1270475071000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Pegylated Interferon in Children and adolescents Infected with Chronic Hepatitis C"],"prefix":"10.1177","volume":"24","author":[{"given":"Doa\u2019a Hamed","family":"Abdel-Aziz","sequence":"first","affiliation":[{"name":"National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmeen Ahmed","family":"Sabry","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal Hamdy","family":"El-Sayed","sequence":"additional","affiliation":[{"name":"Department of Paediatric Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omima Naiem","family":"El-Gazayerly","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,4,2]]},"reference":[{"key":"bibr1-0897190010367737","unstructured":"Koop CE. Hepatitis C: an epidemic for anyone. http:\/\/www.epidemic.org\/theFacts\/theEpidemic\/worldPrevalence. Accessed July 6, 2009."},{"key":"bibr2-0897190010367737","unstructured":"World Health Organization (WHO). Hepatitis C: 170 million infected worldwide and still no vaccine. WHO\/36. Geneva, Switzerland: WHO; May 1, 1998."},{"key":"bibr3-0897190010367737","first-page":"28","volume":"26","author":"National Institutes of Health Consensus Development Conference Panel Statement","year":"1997","journal-title":"Hepatology"},{"key":"bibr4-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.9714"},{"key":"bibr5-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(97)90070-5"},{"key":"bibr6-0897190010367737","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2000.63.236"},{"key":"bibr7-0897190010367737","first-page":"98","volume":"18","author":"El-Zayadi AR","year":"1997","journal-title":"Trop Gastroenterol"},{"key":"bibr8-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.20797"},{"key":"bibr9-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200108000-00006"},{"key":"bibr10-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410802"},{"key":"bibr11-0897190010367737","first-page":"41","volume":"3","author":"Mohamed MK","year":"2004","journal-title":"Afro Arab Liver J"},{"key":"bibr12-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgm177"},{"key":"bibr13-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506013322202"},{"key":"bibr14-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007265"},{"key":"bibr15-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"bibr16-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"bibr17-0897190010367737","unstructured":"Antiviral Drugs Advisory Committee: Transcript May 4-6, 1998. http:\/\/www.fda.gov\/OHRMS\/DOCKETS\/ac\/cder98t.htm"},{"key":"bibr18-0897190010367737","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0168-8278(99)80154-8","volume":"30","year":"1999","journal-title":"J Hepatol"},{"key":"bibr19-0897190010367737","unstructured":"Mukherjee S. Hepatitis C. http:\/\/emedicine.medscape.com\/article\/177792-overview. Last updated June 2009. Accessed July 2009."},{"key":"bibr20-0897190010367737","first-page":"B303","volume":"26","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"bibr21-0897190010367737","volume-title":"Consensus Development Conference Statement: Management of Hepatitis C","author":"National Institutes of Health","year":"2002"},{"key":"bibr22-0897190010367737","first-page":"15","volume":"66","author":"Michielsen P","year":"2003","journal-title":"Acta Gastroenterol Belg"},{"key":"bibr23-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199608000-00001"},{"key":"bibr24-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20661"},{"key":"bibr25-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31802dd2f6"},{"key":"bibr26-0897190010367737","unstructured":"Declaration of Helsinki. Current (2008) version. http:\/\/www.wma.net\/e\/policy\/pdf\/17c.pdf. Accessed August 2009."},{"key":"bibr27-0897190010367737","unstructured":"European Medicines Agency. Guideline for Good Clinical Practice. CPMP\/ICH\/135\/95, July 2002. http:\/\/www.emea.europa.eu\/pdfs\/human\/ich\/013595en.pdf. Accessed August 2009."},{"key":"bibr28-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"bibr29-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fa759f"},{"key":"bibr30-0897190010367737","unstructured":"Neutropenia: causes, consequences, and care, supported by the Neutropenia Association Inc. 1993. http:\/\/www.neutropenia.ca\/about\/index.html. Accessed August 2009."},{"key":"bibr31-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280534"},{"key":"bibr32-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199404000-00005"},{"key":"bibr33-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000235974.67496.e6"},{"key":"bibr34-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22679"},{"key":"bibr35-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1458"},{"key":"bibr36-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36495"},{"key":"bibr37-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1086\/313709"},{"key":"bibr38-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1542\/peds.106.4.e53"},{"key":"bibr39-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200202000-00018"},{"key":"bibr40-0897190010367737","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20884"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190010367737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190010367737","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190010367737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:34:25Z","timestamp":1777509265000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190010367737"}},"subtitle":["A Preliminary Study"],"short-title":[],"issued":{"date-parts":[[2010,4,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1177\/0897190010367737"],"URL":"https:\/\/doi.org\/10.1177\/0897190010367737","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,2]]}}}